<?xml version='1.0' encoding='UTF-8' standalone='no'?>
<rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:bqbiol="http://biomodels.net/biology-qualifiers/" xmlns:collex="http://www.collex.org/schema#" xmlns:bqmodel="http://biomodels.net/model-qualifiers/" xmlns:scoro="http://purl.org/spar/scoro/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:biomodel="http://biomodels.net/model-qualifiers/">
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:title>Grossman, Feinberg, Kuznetsov, Dimitrov, Paul, 1998</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>immunology</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>pathology</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>virus dynamics</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>therapy</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>hiv-1</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>viral dynamics</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <prism:keyword>drug combination therapy</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:description>#### Model Status



 This is the original unchecked version of the model imported from the previous
 CellML model repository, 24-Jan-2006.
 


#### Model Structure



Highly active anti-retroviral therapy (HAART) significantly reduces the viral load in most HIV infected patients. Most believe that this is due to the drug's ability to act as an efficient blockade of the *de novo* infection of target cells. However, HAART is not 100 percent effective, usually because some long-lived infected cells persist, which then convert to short-lived HIV producers when activated. The extent to which virus production from infected to uninfected cells is blocked is of great importance. The answer will help to determine whether or not HAART is capable of eradicating HIV infection.




The concept that drug treatment is an efficient blockade of viral replication has derived much of its credibility from being incorporated into a model that successfully fits the kinetic data. This model of HIV dynamics was published by [Perelson *et al.* in 1996](http://www.cellml.org/models/perelson_neumann_markowitz_leonard_ho_1996_version01). Their main observation was that viral load decline following drug application occurred in two discrete phases: an initial rapid decline (phase I) followed by a more gradual decline (phase II). They explained this observation by the fact that the drugs decreased viral load by inhibiting the *de novo* infection of susceptible cells. Phase I reflected the decline of the originally infected cells, and phase II reflected the decline of those infected cells which had a slightly longer half-life.




However, the authors of the current model, Grossman *et al.* argue that the idea of a cell having a half-life is biologically implausible. They suggest instead that it is more plausible to think of the infected lymphocytes undergoing an aging-like process. That is, the death of an infected, HIV-producing cell follows productive infection after a time delay (see 
 the figure
 below). The observed exponential decline in viral load then requires an alternative explanation. This is provided by assuming that *de novo* infection is not blocked completely by HAART, but only reduced. 




The complete original paper reference is cited below:




[HIV infection: how effective is drug combination treatment?](http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6VHW-3V5VD9Y-C&amp;_user=140507&amp;_coverDate=11%2F01%2F1998&amp;_alid=132243356&amp;_rdoc=1&amp;_fmt=summary&amp;_orig=search&amp;_qd=1&amp;_cdi=6077&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_acct=C000011498&amp;_version=1&amp;_urlVersion=0&amp;_userid=140507&amp;md5=bd6c63528fd70efcdefe0d2be162ea9f), Zvi Grossman, Mark Feinberg, Vladimir Kuznetsov, Dimiter Dimitrov, and William Paul, 1998, [*Immunology Today*](http://www.sciencedirect.com/science?_ob=JournalURL&amp;_cdi=6077&amp;_auth=y&amp;_acct=C000011498&amp;_version=1&amp;_urlVersion=0&amp;_userid=140507&amp;md5=97e17db3f48862ce8ba63183f14ecd55), 19, 528-532. ([Full text (HTML)](http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6VHW-3V5VD9Y-C&amp;_user=140507&amp;_coverDate=11%2F01%2F1998&amp;_alid=132243356&amp;_rdoc=1&amp;_fmt=full&amp;_orig=search&amp;_qd=1&amp;_cdi=6077&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_acct=C000011498&amp;_version=1&amp;_urlVersion=0&amp;_userid=140507&amp;md5=73cecab5084cdcdc9ae558e99e9a43b6) and PDF versions of the article are available on the *Immunology Today* website.) [PubMed ID: 9818549](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9818549&amp;dopt=Abstract)




Model simulations revealed that the half-life of the infected cells can be calculated with reasonable accuracy from clinical data. However, the remaining parameters can not be accurately predicted from the current model, more data is needed. 




A variable delay from productive cell infection to cell death can be modelled by dividing the process into several sequential stages. These stages may represent real stages in the infection process, or they may be regarded as a modelling convenience. Another method of modelling a variable delay is to introduce a distribution of delay times around a fixed average. This is the approach chosen by the authors of the current model.</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <collex:thumbnail rdf:resource="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_1998.png">http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_1998.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <rdfs:label>Zvi Grossman</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <foaf:name>Zvi Grossman</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:creator rdf:resource="local:00001">local:00001</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <rdfs:label>Mark Feinberg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <foaf:name>Mark Feinberg</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:creator rdf:resource="local:00002">local:00002</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <rdfs:label>Vladimir Kuznetsov</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <foaf:name>Vladimir Kuznetsov</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:creator rdf:resource="local:00003">local:00003</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <rdfs:label>Dimiter Dimitrov</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <foaf:name>Dimiter Dimitrov</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:creator rdf:resource="local:00004">local:00004</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <rdfs:label>William Paul</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <foaf:name>William Paul</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:creator rdf:resource="local:00005">local:00005</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <rdfs:label>Catherine Lloyd</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <foaf:name>Catherine Lloyd</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:contributor rdf:resource="local:00006">local:00006</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <dc:identifier rdf:resource="http://identifiers.org/orcid:0000-0001-5801-5510">http://identifiers.org/orcid:0000-0001-5801-5510</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <rdfs:label>Bilal Shaikh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <foaf:accountName rdf:resource="https://orcid.org/0000-0001-5801-5510">https://orcid.org/0000-0001-5801-5510</foaf:accountName>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <foaf:name>Bilal Shaikh</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:contributor rdf:resource="local:00007">local:00007</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <dc:identifier rdf:resource="https://identifiers.org/pmr:3170c283f73b04cbd2916585775e0f6e">https://identifiers.org/pmr:3170c283f73b04cbd2916585775e0f6e</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <rdfs:label>PMR: 3170c283f73b04cbd2916585775e0f6e</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <bqmodel:is rdf:resource="local:00008">local:00008</bqmodel:is>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <dc:identifier rdf:resource="https://identifiers.org/doi/10.1016/s0167-5699(98)01353-x">https://identifiers.org/doi/10.1016/s0167-5699(98)01353-x</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <rdfs:label>Zvi Grossman, Mark Feinberg, Vladimir Kuznetsov, Dimiter Dimitrov &amp; William Paul. HIV infection: how effective is drug combination treatment? Immunology Today 19, 11: 528-532 (1998).</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00009">local:00009</bqmodel:isDescribedBy>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:license rdf:resource="local:00010">local:00010</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex">
    <dc:created>2009-06-16T22:28:22</dc:created>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml">
    <dc:title>HIV infection: how effective is drug combination treatment?</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml">
    <dc:description>#### Model Status



 This is the original unchecked version of the model imported from the previous
 CellML model repository, 24-Jan-2006.
 


#### Model Structure



Highly active anti-retroviral therapy (HAART) significantly reduces the viral load in most HIV infected patients. Most believe that this is due to the drug's ability to act as an efficient blockade of the *de novo* infection of target cells. However, HAART is not 100 percent effective, usually because some long-lived infected cells persist, which then convert to short-lived HIV producers when activated. The extent to which virus production from infected to uninfected cells is blocked is of great importance. The answer will help to determine whether or not HAART is capable of eradicating HIV infection.




The concept that drug treatment is an efficient blockade of viral replication has derived much of its credibility from being incorporated into a model that successfully fits the kinetic data. This model of HIV dynamics was published by [Perelson *et al.* in 1996](http://www.cellml.org/models/perelson_neumann_markowitz_leonard_ho_1996_version01). Their main observation was that viral load decline following drug application occurred in two discrete phases: an initial rapid decline (phase I) followed by a more gradual decline (phase II). They explained this observation by the fact that the drugs decreased viral load by inhibiting the *de novo* infection of susceptible cells. Phase I reflected the decline of the originally infected cells, and phase II reflected the decline of those infected cells which had a slightly longer half-life.




However, the authors of the current model, Grossman *et al.* argue that the idea of a cell having a half-life is biologically implausible. They suggest instead that it is more plausible to think of the infected lymphocytes undergoing an aging-like process. That is, the death of an infected, HIV-producing cell follows productive infection after a time delay (see 
 the figure
 below). The observed exponential decline in viral load then requires an alternative explanation. This is provided by assuming that *de novo* infection is not blocked completely by HAART, but only reduced. 




The complete original paper reference is cited below:




[HIV infection: how effective is drug combination treatment?](http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6VHW-3V5VD9Y-C&amp;_user=140507&amp;_coverDate=11%2F01%2F1998&amp;_alid=132243356&amp;_rdoc=1&amp;_fmt=summary&amp;_orig=search&amp;_qd=1&amp;_cdi=6077&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_acct=C000011498&amp;_version=1&amp;_urlVersion=0&amp;_userid=140507&amp;md5=bd6c63528fd70efcdefe0d2be162ea9f), Zvi Grossman, Mark Feinberg, Vladimir Kuznetsov, Dimiter Dimitrov, and William Paul, 1998, [*Immunology Today*](http://www.sciencedirect.com/science?_ob=JournalURL&amp;_cdi=6077&amp;_auth=y&amp;_acct=C000011498&amp;_version=1&amp;_urlVersion=0&amp;_userid=140507&amp;md5=97e17db3f48862ce8ba63183f14ecd55), 19, 528-532. ([Full text (HTML)](http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6VHW-3V5VD9Y-C&amp;_user=140507&amp;_coverDate=11%2F01%2F1998&amp;_alid=132243356&amp;_rdoc=1&amp;_fmt=full&amp;_orig=search&amp;_qd=1&amp;_cdi=6077&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_acct=C000011498&amp;_version=1&amp;_urlVersion=0&amp;_userid=140507&amp;md5=73cecab5084cdcdc9ae558e99e9a43b6) and PDF versions of the article are available on the *Immunology Today* website.) [PubMed ID: 9818549](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9818549&amp;dopt=Abstract)




Model simulations revealed that the half-life of the infected cells can be calculated with reasonable accuracy from clinical data. However, the remaining parameters can not be accurately predicted from the current model, more data is needed. 




A variable delay from productive cell infection to cell death can be modelled by dividing the process into several sequential stages. These stages may represent real stages in the infection process, or they may be regarded as a modelling convenience. Another method of modelling a variable delay is to introduce a distribution of delay times around a fixed average. This is the approach chosen by the authors of the current model.</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_1998.png">http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_1998.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml">
    <dc:license rdf:resource="local:00011">local:00011</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/simulation_0.sedml">
    <dc:title>Simulation 0</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/simulation_0.sedml">
    <dc:description>Automatically generated SED-ML file for model grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <rdfs:label>CC BY 4.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/simulation_0.sedml">
    <dc:license rdf:resource="local:00012">local:00012</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/simulation_0.sedml">
    <bqmodel:isDerivedFrom rdf:resource="local:00013">local:00013</bqmodel:isDerivedFrom>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <dc:description>isDerivedFrom</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <dc:identifier rdf:resource="http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml">http://omex-library.org/3170c283f73b04cbd2916585775e0f6e.omex/grossman_feinberg_kuznetsov_dimitrov_paul_1998.cellml</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <rdfs:label>grossman_feinberg_kuznetsov_dimitrov_paul_1998</rdfs:label>
  </rdf:Description>
</rdf:RDF>
